@beatalleukemia
Clonal Hematopoesis,MDS,AML @OSUCCC_James Acute Leukemia Clinical Section Head and Clinical Research Director. Girl Mom, Vegetarian, Avid Reader, Traveller & Adventurer
How fortunate are we to have @kimrynrathmell.bsky.social
bring her wealth of experience & outstanding leadership to @osucccjames.bsky.social
@osuwexmed.bsky.social ! Welcome to #BuckeyeNation Dr. Rathmell! @osuhematology.bsky.social
The closest I’m ever going to come to a National Football Championship Trophy ! 🙏🏽 @Peletonia @Huntington_Bank @OhioStateFB Proud to be a Peletonia funded @osuhematology.bsky.social @osucccjames.bsky.social Researcher & part of #BuckeyeNation
What other kinds of presentations are there (other than fabulous ? ) Clearly, I have been attending the wrong conferences so far without fabulous presentations 😂
a nice analysis from the BEAT AML study outlining molecular characteristics of adults >60 with AML
www.nature.com/articles/s41...
Hi.
Books are incredibly important.
Please let them be.
helpful sub-group analysis of Aza + Ven studies looking at treatment-naive t-AML and AML arising from MDS or CMML!
www.nature.com/articles/s41...
Very proud to have played a role in this study with my study chair Dr. Eric Huselton from University of Rochester - please consider your patients for this study @osuhematology.bsky.social @osucccjames.bsky.social @swog.org @ash.hematology.org
If you know anyone that takes Sprycell, please let them know !!!
A great @bloodjournal.bsky.social paper by @beatalleukemia.bsky.social et al on clinical trial eligibility for patients with MDS!
ashpublications.org/blood/articl...
Thrilled to see our effort on behalf of @ic_MDS group out in @BloodJournal about reducing clinical trial eligibility barriers for our MDS patients. Commentary by Lionel Ades on ‘ releasing the brake’ on eligibility criteria. @Dr_AmerZeidan #mdssm ashpublications.org/blood/article/…
Happy CD3 CD28 T Cell Stimulation Day to all who celebrate
Calling all hematologists - how are you interpreting the results of the TRAIN trial vs the SAHARA trial in patients with blood cancers & acute cerebral bleeding events ?
jamanetwork.com/journals/jam...
www.nejm.org/doi/full/10....
@shematologist.medsky.social @bloodman.bsky.social
Sunset & snow makes for good hunting.#springbreak
I would be the second to last one 😂
a very nice review in AJH on considerations of MPN management in women!
onlinelibrary.wiley.com/doi/full/10....
👇🏾
Researchers at Brigham and Women's Hospital, Boston, recently found that ANC in 120 people with the Duffy null blood group can range from 1210-5390 microliters: significantly lower than most institutional reference ranges
Historically, ANC reference ranges have had a lower limit of 2000 microliters, but these were based on studies in populations with European ancestry, in whom the Duffy null phenotype is rare.
2/3 of people in the USA who self-identify as African-American have the Duffy null phenotype. It is also more common in people of Middle East and North African ancestry.
Could adjusting a simple blood test reference range save patients unnecessary stress?
Recent research highlights Duffy null-associated neutrophil count (DANC) and the risk it imposes on certain ancestral backgrounds.
Enroll in the ASH course: bit.ly/duffynull
#HemeSky #Hematology #MedSky
The 2025 @castleconnolly.bsky.social Exceptional Women in Medicine is out!🎉This honor celebrates🔝female physicians for their leadership & expertise.
👏 Congrats to the OSUCCCJames Heme honorees:
Jennifer Woyach
Uma Borate @beatalleukemia.bsky.social
Alice Mims
Ashley Rosko
Kami Maddocks
Kerry Rogers
Love @leegrimeslab.bsky.social for representing!!
EST to PST problems. Awake 3 hrs before #ASH24 activities start but very excited for our Scientific Workshop on DCTs & AI from 2-5 pm today! If you are a trial sponsor , investigator , statistician or involved in any clinical research- this one is ‘A must attend’ ! #DCTs
Great haiku! The excitement for #ASH24 will power us through this early morning!
I posted the exact same thing except in an ASHaiku 😂
Waking up before the crack of dawn
EST to PST
Excited for #ASH24
#ASHaiku
Our DCT and AI Scientific Workshop on Friday! Come see us !!
Our Friday Scientific Workshop on Real World DCTs in Hematology &AI has a fantastic line up of speakers : clinical trialists ( IIT PIs included) statisticians, pharma sponsors, & regulatory experts discussing all things practical about hematology DCTs - join us ! 👇🏾#ASH24
go.bsky.app/Avv8xad I made this starter pack for any myeloid malignancy academics to find others - please share & add to this !
🩸 CHIP, CCUS, & ICUS quick definitions:
CHIP
- leukemia-associated gene mutation w/ VAF ≥ 2%
- normal blood counts
- no dx of another hematologic malignancy
CCUS = CHIP with ≥ 1 cytopenias
ICUS
≥ 1 cytopenias + 🚫 identifiable mutation
#hemesky #MedSky #IMsky
I’m going !
📢 Don’t miss Ohio State’s 2024 Scarlet and Gray Reception at the National ASH Meeting! 🌟
Network, connect, and celebrate with us. 🗓️ Register now: osu.az1.qualtrics.com/jfe/form/SV_8H…
#ASH24 #BuckeyePride #ScarletAndGray
www.nejm.org/doi/full/10....
Such an important article addressing why certain groups may receive differing medical treatment including access to clinical trials.
